Cargando…
P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431113/ http://dx.doi.org/10.1097/01.HS9.0000970624.05231.6a |
| _version_ | 1785091122970755072 |
|---|---|
| author | Leleu, Xavier Iida, Shinsuke Ola Landgren, C. Lesokhin, Alexander Leip, Eric Kudla, Arthur Finn, Gregory Qiu, Lugui |
| author_facet | Leleu, Xavier Iida, Shinsuke Ola Landgren, C. Lesokhin, Alexander Leip, Eric Kudla, Arthur Finn, Gregory Qiu, Lugui |
| author_sort | Leleu, Xavier |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431113 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104311132023-08-17 P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2 Leleu, Xavier Iida, Shinsuke Ola Landgren, C. Lesokhin, Alexander Leip, Eric Kudla, Arthur Finn, Gregory Qiu, Lugui Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431113/ http://dx.doi.org/10.1097/01.HS9.0000970624.05231.6a Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Leleu, Xavier Iida, Shinsuke Ola Landgren, C. Lesokhin, Alexander Leip, Eric Kudla, Arthur Finn, Gregory Qiu, Lugui P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2 |
| title | P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2 |
| title_full | P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2 |
| title_fullStr | P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2 |
| title_full_unstemmed | P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2 |
| title_short | P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2 |
| title_sort | p930: elranatamab monotherapy or in combination with daratumumab vs daratumumab + pomalidomide + dexamethasone for patients with relapsed/refractory multiple myeloma: phase 3 magnetismm-5 study, part 2 |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431113/ http://dx.doi.org/10.1097/01.HS9.0000970624.05231.6a |
| work_keys_str_mv | AT leleuxavier p930elranatamabmonotherapyorincombinationwithdaratumumabvsdaratumumabpomalidomidedexamethasoneforpatientswithrelapsedrefractorymultiplemyelomaphase3magnetismm5studypart2 AT iidashinsuke p930elranatamabmonotherapyorincombinationwithdaratumumabvsdaratumumabpomalidomidedexamethasoneforpatientswithrelapsedrefractorymultiplemyelomaphase3magnetismm5studypart2 AT olalandgrenc p930elranatamabmonotherapyorincombinationwithdaratumumabvsdaratumumabpomalidomidedexamethasoneforpatientswithrelapsedrefractorymultiplemyelomaphase3magnetismm5studypart2 AT lesokhinalexander p930elranatamabmonotherapyorincombinationwithdaratumumabvsdaratumumabpomalidomidedexamethasoneforpatientswithrelapsedrefractorymultiplemyelomaphase3magnetismm5studypart2 AT leiperic p930elranatamabmonotherapyorincombinationwithdaratumumabvsdaratumumabpomalidomidedexamethasoneforpatientswithrelapsedrefractorymultiplemyelomaphase3magnetismm5studypart2 AT kudlaarthur p930elranatamabmonotherapyorincombinationwithdaratumumabvsdaratumumabpomalidomidedexamethasoneforpatientswithrelapsedrefractorymultiplemyelomaphase3magnetismm5studypart2 AT finngregory p930elranatamabmonotherapyorincombinationwithdaratumumabvsdaratumumabpomalidomidedexamethasoneforpatientswithrelapsedrefractorymultiplemyelomaphase3magnetismm5studypart2 AT qiulugui p930elranatamabmonotherapyorincombinationwithdaratumumabvsdaratumumabpomalidomidedexamethasoneforpatientswithrelapsedrefractorymultiplemyelomaphase3magnetismm5studypart2 |